Publications by authors named "M S Schinkelshoek"
Article Synopsis
- * There's a possibility that an autoimmune process is involved, but tests for specific autoantibodies and T-cells haven't provided clear answers; other factors, like reduced hormone production in the brain, are also being considered.
- * Currently, there is no cure for NT1, and treatment focuses on managing symptoms; however, new hypocretin receptor agonists are showing promise in clinical trials, highlighting the need for better understanding and early diagnosis to improve treatment outcomes, especially in children
Aim Of The Study: The primary purpose was to examine sleep difficulties and delirium in the Intensive and Intermediate Care Unit. Secondarily, factors impacting night-time sleep duration and quality, mortality, and the impact of benzodiazepine use on sleep outcomes were investigated.
Materials And Methods: This retrospective study encompassed data from 323 intensive and intermediate care unit admissions collected in the Netherlands, spanning from November 2018 to May 2020.
Objectives/background: Narcolepsy type 1 (NT1) is an immune-mediated disorder characterized by excessive daytime sleepiness, cataplexy, low levels of hypocretin-1 in the cerebrospinal fluid, and a strong association with the HLA DQB1*06:02 allele. There is evidence for streptococcal infections as one pathogenic factor that may lead to NT1 as part of a multifactorial pathogenesis. Elevated titers of Antistreptolysin-O antibodies and increased inflammatory activity in response to streptococci antigens have been described in patients with NT1.
View Article and Find Full Text PDFExcessive daytime sleepiness is the core symptom of central disorders of hypersomnolence (CDH) and can directly impair driving performance. Sleepiness is reflected in relative alterations in distal and proximal skin temperature. Therefore, we examined the predictive value of skin temperature on driving performance.
View Article and Find Full Text PDF